AUG 10, 2020 8:18 AM PDT

A New Prognostic Biomarker for Paclitaxel Sensitivity in Breast Cancer

WRITTEN BY: Jasper Cantrell

Breast cancer is one of the deadliest cancers globally. It has been studied extensively with plenty of treatments available. Cancers tend to have subtle characteristics that can make them resistant or sensitive to one form of treatment or another. The key to modern therapy lies in identifying which treatment works best for each patient.

Paclitaxel is a chemotherapy drug that targets the microtubules in a cell and is a first-line treatment for many cancers. Microtubules are an essential component of a cell’s skeleton and play a role in cellular division. Paclitaxel prevents microtubules from functioning properly and is a proven chemotherapy. Unfortunately, it is only effective in 20% of breast cancer patients. Identifying which patients would react favorably to paclitaxel and other such therapies is critical and could cut down on costly ineffective treatment choices.

A team from the Universite Paris-Saclay in France had tackled this problem before and identified the protein ATIP3 as a biomarker to predict if a breast cancer patient has a taxane sensitive tumor. ATIP3 is a protein involved in microtubule stabilization. When levels were low in a cancer, it was paclitaxel sensitive, although it had a more aggressive nature. In a new study, they investigated why low ATIP3 levels were a marker of paclitaxel sensitivity.

They began by examining how taxane-based chemotherapy affected a cohort of breast cancer patients. ATIP3 deficient patients had decreased metastasis after treatment, compared to others of the cohort that showed no change in metastasis post-treatment. Cell assays found that ATIP3 managed to improve paclitaxel’s anti-metastatic activity by increasing paclitaxel accumulation within the cell itself.

This study managed to identify that ATIP3 deficiency caused paclitaxel to accumulate in cells. They note that other studies have seen similar results with other microtubule destabilizers. One group even showed that the addition of a destabilizer could increase paclitaxel’s effectiveness in vitro. What makes ATIP3 deficiency unique is that it can be tested for, making it a potential biomarker for taxane sensitive breast cancers.

The study concludes, “we show here that ATIP3 deficiency in breast cancer facilitates paclitaxel accumulation on the microtubule lattice of interphase cells, and improves the anti-migratory and anti-metastatic effects of the drug.” With further validation, ATIP3 testing could give patients more options for a tailored therapy that is right for them.

Sources: Nature Scientific Reports, OncLiveTV

 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
DEC 16, 2020
Cancer
More young adults are being diagnosed with esophageal adenocarcinoma
DEC 16, 2020
More young adults are being diagnosed with esophageal adenocarcinoma
New research published in a journal of the American Association for Cancer Research, Cancer Epidemiology, Biomarkers &am ...
JAN 12, 2021
Cell & Molecular Biology
Hyperactive Mitochondria Can Fuel Brain Tumors
JAN 12, 2021
Hyperactive Mitochondria Can Fuel Brain Tumors
The most common and deadly form of brain cancer is known as glioblastoma; the median survival time for patients is only ...
JAN 08, 2021
Chemistry & Physics
Detecting tumors from the shear waves emitted by song
JAN 08, 2021
Detecting tumors from the shear waves emitted by song
Will a singing test be the way the doctors of the future monitor thyroid health? According to a collaboration of researc ...
JAN 17, 2021
Cancer
Analyzing the role of our circadian clocks in prostate cancer
JAN 17, 2021
Analyzing the role of our circadian clocks in prostate cancer
Research published recently in Nature Communications looks into the role that circadian rhythms play on prostate cancer ...
JAN 22, 2021
Clinical & Molecular DX
Breast Cancer's Nasty Nine Revealed
JAN 22, 2021
Breast Cancer's Nasty Nine Revealed
Calculating an individual’s risk of developing breast cancer isn’t easy. There’s a complex interplay b ...
FEB 16, 2021
Clinical & Molecular DX
What Dead Cells Can Tell Us About Our Health
FEB 16, 2021
What Dead Cells Can Tell Us About Our Health
Taking a sample of tissue called a biopsy from an organ suspected of harboring a pathology is a common diagnostic practi ...
Loading Comments...